AK112 drug page Clinical trials

Trials with AK112

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

8Trials
3Recruiting
2Countries
1.589Planned patients

Showing 1–8 of 8

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Recruiting Phase 3 560 patients NCT06951503

This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.

China May 2025 – Jan 2029 Interventional
Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer
Recruiting Phase 2 100 patients NCT06718543

This phase II multicenter, randomized study evaluates the safety and efficacy of neoadjuvant short-course radiotherapy (SCRT) sequentially combined with AK112 (Envafolimab) with or without chemotherapy in patients with locally advanced rec…

China Feb 2025 – Oct 2027 Interventional
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Recruiting Phase 1 87 patients NCT05689853

This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.

China Apr 2023 – Jun 2027 Interventional
Combined with: AK119
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases
Not yet recruiting Phase 1 72 patients NCT07357220

An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.

China Mar 2026 – Feb 2028 Interventional
Combined with: VG2025
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Not yet recruiting Phase 2 130 patients NCT07021950

This study is a multicenter, open-label phase II trial conducted to assess the safety and antitumor activity of Ivonescimab (AK112) plus FOLFIRI versus bevacizumab plus FOLFIRI as second-line treatment in subjects with MSS/pMMR metastatic …

Aug 2025 – Dec 2028 Interventional
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Ongoing, not recruiting Phase 1 216 patients NCT05951608

A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors

China Oct 2023 – Aug 2026 Interventional
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Ongoing, not recruiting Phase 1 170 patients NCT05846867

This is an open label, multicenter Phase Ib/II clinical study on the efficacy and safety of AK119 and AK112 in combination with or without chemotherapy, and AK112 monotherapy in pMMR/MSS CRC

China May 2023 – Aug 2026 Interventional
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Ongoing, not recruiting Phase 2 254 patients NCT05382442

This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.

United States, China Jun 2022 – Aug 2028 Interventional

Where the recruiting trials are